Letters, Testimony & Comments
The Biotechnology Industry Organization (BIO) is pleased to submit the following...
December 21 2012
Dear Commissioner Hamburg:
We are writing on behalf of the following higher education associations in consideration of issues raised...
November 5 2012
Re: Patient-Centered Outcomes Research Institute (PCORI) Draft Methodology Report
Dear Dr. Selby:
The Biotechnology Industry...
September 13 2012
Re: CMS-2345-P (Proposed Rule, Medicaid Program; Covered Outpatient Drugs)
Dear Ms. Tavenner:
The...
April 1 2012
Chairman Harkin, Ranking Member Enzi, Members of the Committee, it is my privilege to provide testimony before you today. My name...
March 29 2012
RE: Patient-Centered Outcomes Research Institute (PCORI) Draft National Priorities and Research Agenda
Dear Dr. Selby:
...
March 14 2012
Re: Draft 2013 Call Letter
Dear Mr. Blum and Mr. Spitalnic:
The Biotechnology Industry Organization (BIO) appreciates this...
March 2 2012
February 22, 2012
Texas Health and Human Services Commission
Attn: Stacey Johnston
Policy Analyst
Medicaid/Children’s Health...
March 1 2012
BIO Public Statement: National Patient and Stakeholder Dialogue
Thank you for the opportunity to present comments on behalf...
February 27 2012
The Biotechnology Industry Organization (BIO) is pleased to submit the following comments on the Department of Health and Human Services...
January 31 2012
Re: CED Public Solicitation
Dear Dr. Jacques:
...
January 20 2012
Thank you for the opportunity to present comments on behalf of the innovative biotechnology industry which is working to prevent, treat,...
October 25 2011
RE: June 29, 2011 Memorandum on Proposed Changes to the Medicare Coverage Gap Discount Program – Low-Volume...
August 1 2011
July 19, 2011
BIO’s comments addressed maters such as HRSA’s application of the exclusion, operational concerns arising from the proposed...
July 19 2011
June 15, 2011
Re: Proposed Guidance Regarding Branded Prescription Drug Fee [Notice 2011-9]
Dear Mr. Commissioner:
The Biotechnology Industry...
June 15 2011
June 6, 2011
Re: Medicare Program; Medicare Shared Saving Program: Accountable Care Organizations; Proposed Rule [CMS-1345-P]
Dear Dr. Berwick:...
June 6 2011
April 29, 2011
Re: Proposed Guidance Regarding Branded Prescription Drug Fee [Notice 2011-9]
Dear Mr. Commissioner:
The Biotechnology Industry...
April 29 2011
April 7, 2011
Re: Comments on Section 6002 of the Affordable Care Act
Dear Sir or Madam:
BIO appreciates the opportunity to comment on the...
April 7 2011
December 6, 2010
Institute of Medicine
Essential Health Benefits
BIO Comments
1. What is your interpretation of the word “essential” in...
December 6 2010
September 30, 2010
Dear Ms. Maloy,
As President and CEO of the Biotechnology Industry Organization (BIO) and on behalf of our more than 1,100...
September 30 2010
September 17, 2010
Re: Interim Final Rules for Group Health Plans and Health Insurance Issuers Relating to Coverage of Preventive Services under the Patient...
September 17 2010
August 16, 2010
BIO recommends that each grandfathered health plan disclose which insurance products it offers and cover preventive services and vaccines...
August 16 2010
July 16, 2010
BIO comments on the Medicare Coverage Gap Discount Program Draft Third Party Administrator Agreement (TPA Agreement) and the Draft Data...
July 16 2010
June 21, 2010
Re: Medicare Coverage Gap Discount Program Model Manufacturer Agreement – [CMS-4151-NC] RIN 0938-AQ04
Dear Administrator Tavenner...
June 21 2010
May 14, 2010
BIO supports the coverage gap discount program and believes that it will increase patient access to life-saving and life enhancing...
May 14 2010
Letters, Testimony & Comments
December 21 2012
The Biotechnology Industry Organization (BIO) is pleased to submit the following...
November 5 2012
Dear Commissioner Hamburg:
We are writing on behalf of the following higher education associations in consideration of issues raised...
September 13 2012
Re: Patient-Centered Outcomes Research Institute (PCORI) Draft Methodology Report
Dear Dr. Selby:
The Biotechnology Industry...
April 1 2012
Re: CMS-2345-P (Proposed Rule, Medicaid Program; Covered Outpatient Drugs)
Dear Ms. Tavenner:
The...
March 29 2012
Chairman Harkin, Ranking Member Enzi, Members of the Committee, it is my privilege to provide testimony before you today. My name...
Press Releases
June 28 2012
Pleased to move forward on biosimilars pathway
Washington, D.C. (June 28, 2012) –Biotechnology...
February 15 2012
Washington, DC (February 15, 2012) – Today, the Biotechnology Industry Organization (BIO) praised Sen. Kay...
March 22 2010
WASHINGTON, D.C. (Monday, March 22, 2010) - Biotechnology Industry Organization (BIO) President and CEO Jim...
December 24 2009
WASHINGTON, D.C. (Friday, December 25, 2009) - Biotechnology Industry Organization (BIO) President and CEO Jim...
October 15 2009
WASHINGTON, D.C. (Thursday, October 15, 2009) - The Biotechnology Industry Organization (BIO) today announced Plenary...
Receive our newsletter from BIOtechNOW
Business Solutions Sponsor
